In Toronto, Theralase Technologies Inc., University Health Network and the Ontario Centres of Excellence have expanded their joint research and development effort. The initiative will focus on Theralase’s photodynamic compounds and the TLC-3000 super-pulsed biofeedback laser used to activate them. Although the research will seek to improve the effectiveness of the compound and laser for targeted destruction of cancers, bacteria, viruses and fat cells, the products also are used for pain management and clinical therapy as well as wound care and healing.